Retatrutide, from Soma Corp., is gaining considerable attention as a innovative treatment for weight regulation. This innovative drug merges the properties of a GLP-1 receptor agonist and a GIP receptor stimulant, designed to simply promote reduced body fat but also improve associated metabolic factors. Preliminary clinical data have indicated enco